

Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (#CAG-00066N)

Report from September 27, 2000 Meeting

- Subject:** Ocular Photodynamic Therapy (OPT) with Verteporfin
- Purpose:** Meet with representatives from Covance Health Economics and Outcomes Services, Inc. and QLT PhotoTherapeutics, Inc. as well as several leading clinicians and researchers on the topic of age-related macular degeneration (AMD).
- Date:** September 27, 2000; 10:30 a.m.-12:00 p.m.
- Place:** Health Care Financing Administration (HCFA)
- Participants:** HCFA: Richard Coyne, Jackie Sheridan, Shana Olshan, Svati Patel, Poppy Rotter, Mitchell Burken, Erica Bisguier-Reed, Vanessa Taneyhill, and Mike Londner.
- Non-HCFA: Lee Jampal (Northwestern University), Philip Rosenfeld (University of Miami), Neil Bressler (Johns Hopkins University), Luis Gutierrez (Covance), Bob Butchofsky (QLT, Inc.), Mohammad Azah (QLT, Inc.), Grant Bagley (Arnold & Porter), and Patricia Levy (Covance).
- Summary:** This meeting was held to discuss the HCFA's coverage review (CAG-00066) of OPT with verteporfin. The principal investigators for the Treatment of AMD with Photodynamic Therapy (TAP) trial provided an overview of AMD, discussed the trial's design and results, and answered questions posed by HCFA. The agenda for this meeting, prepared in advance by Covance, is described below:
- 1) Introduction - Luis Gutierrez
 - 2) Age-Related Macular Degeneration Background - Dr. Phillip Rosenfeld
 - 3) Background on OPT with Verteporfin - Dr. Phillip Rosenfeld
 - 4) Treatment of Choroidal Neovascularization Due to AMD with Verteporfin Therapy - Dr. Neil Bressler
 - 5) Treatment of Choroidal Neovascularization Due to Pathologic Myopia (PM) with

Verteporfin Therapy - Dr. Neil Bressler
6) Current Guidelines and Rationale for
Verteporfin Therapy - Dr. Neil Bressler
7) Critical Policy Issues - Luis Gutierrez
8) Questions/Answers

Prepared by: Svati Patel, CAG, OCSQ, HCFA; (410) 786-
2875; spatel@cms.hhs.gov